IF 4.4 3区医学

Eye Pub Date : 2026-10-05 DOI: 10.1038/s41433-026-04923-1

Massimiliano Borselli, Costanza Rossi, Giuseppe Giannaccare

引用次数: 0

Systematic review of eyecare Patient-Reported Experience Measures (PREMs) following COSMIN guidelines. 遵循COSMIN指南的眼科护理患者报告体验措施（PREMs）的系统评价。

IF 4.4 3区医学

Eye Pub Date : 2026-10-05 DOI: 10.1038/s41433-026-04907-1

Pongnugoon Kongjaidee, Timothy Pickles, Barbara Ryan, Francis W B Sanders, Colm McAlinden, Jennifer H Acton

{"title":"Systematic review of eyecare Patient-Reported Experience Measures (PREMs) following COSMIN guidelines.","authors":"Pongnugoon Kongjaidee, Timothy Pickles, Barbara Ryan, Francis W B Sanders, Colm McAlinden, Jennifer H Acton","doi":"10.1038/s41433-026-04907-1","DOIUrl":"https://doi.org/10.1038/s41433-026-04907-1","url":null,"abstract":"Patient-Reported Experience Measures (PREMs) are essential for assessing healthcare quality from the patient's perspective. However, their use in eyecare is limited. This systematic review aimed to assess the existing evidence on the measurement properties of PREMs used to capture patient experiences of eyecare services. A comprehensive literature search was conducted across Web of Science Core Collection, Embase, PubMed, and Scopus to identify studies reporting the development and/or psychometric evaluation of PREMs in eyecare. The extracted measurement properties encompassed information on item development, content validity (the extent to which items are relevant, comprehensive, and understandable), structural validity (whether the items form the right scales), internal consistency (how well items measure underlying eyecare experience domains), cross-cultural validity, reliability, hypothesis testing, and responsiveness. Quality assessment, evaluation of measurement properties, evidence synthesis, and grading followed COSMIN methodology for systematic reviews. Thirteen studies were included, three of which evaluated 10 distinct PREMs, across settings, including low vision and primary/secondary eyecare. All ten PREMs met criteria for COSMIN Category B (potentially recommended, further validation needed). However, most lacked sufficient evidence for content validity and lacked supporting evidence for structural validity. None demonstrated adequate reliability, and none reported using Item Response Theory or Rasch Measurement Theory. Consequently, there was insufficient evidence to classify any of the identified PREMs into COSMIN recommendation Category A (recommended for use). Future studies on PREMs in eyecare should aim to strengthen the evidence for content and structural validity and provide robust proof of their reliability.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on: 'Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist'. 评论：“玻璃体内药物治疗的药理学原理及其对临床实践的影响：眼科医生的入门读本”。

IF 4.4 3区医学

Eye Pub Date : 2026-10-03 DOI: 10.1038/s41433-026-04922-2

Eva M Del Amo, Víctor Mangas-Sanjuán, Anxo Fernández-Ferreiro

引用次数: 0

Pharmacokinetic and pharmacodynamic considerations of cumulative intravitreal drug exposure of the newer anti-VEGF agents. 新型抗vegf药物的累积玻璃体内药物暴露的药代动力学和药效学考虑。

IF 4.4 3区医学

Eye Pub Date : 2026-10-03 DOI: 10.1038/s41433-026-04914-2

Petros Aristodemou

引用次数: 0

Restorative and regenerative therapies for vision loss. 视力丧失的恢复性和再生疗法。

IF 4.4 3区医学

Eye Pub Date : 2026-10-02 DOI: 10.1038/s41433-026-04913-3

Nikolay Boychev, Jonathan R Soucy, Sally H Dang, Catherine T Tran, Alexis G Malkin, Vincent Yeung, Amy E Ross, Audrey E K Hutcheon, Levi N Kanu

{"title":"Restorative and regenerative therapies for vision loss.","authors":"Nikolay Boychev, Jonathan R Soucy, Sally H Dang, Catherine T Tran, Alexis G Malkin, Vincent Yeung, Amy E Ross, Audrey E K Hutcheon, Levi N Kanu","doi":"10.1038/s41433-026-04913-3","DOIUrl":"https://doi.org/10.1038/s41433-026-04913-3","url":null,"abstract":"Reversing blindness and restoring functional vision remains a central challenge in biomedical engineering. Advances in ocular prosthetics have enabled limited recovery of light perception, motion detection, and coarse object recognition through anterior segment devices such as keratoprostheses and through posterior segment interfaces including retinal, suprachoroidal, optic nerve, and cortical implants. Parallel progress in organ-on-a-chip systems and retinal organoids is providing increasingly sophisticated platforms for disease modelling and therapeutic development. Despite these advances, issues of long-term biocompatibility, signal fidelity, and surgical complexity continue to constrain clinical performance. Emerging approaches that combine stem cell-derived tissues, biofabrication, and hybrid bioelectronic constructs offer promising avenues for next-generation vision restoration, although current production remains limited to early-stage or small-scale systems. Effective integration of these technologies also requires structured vision-rehabilitation strategies to harness neuroplasticity and support functional adaptation. This review synthesises recent progress across prosthetic, rehabilitative, and regenerative domains and outlines key opportunities for future translational development.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 4 macular neovascularisation arising from a congenital toxoplasmosis scar. 由先天性弓形虫病疤痕引起的4型黄斑新生血管。

IF 4.4 3区医学

Eye Pub Date : 2026-10-02 DOI: 10.1038/s41433-026-04963-7

Tanguy Noir, Eric H Souied, Alexandra Miere

引用次数: 0

Thirty-year silicone implant granuloma. 30年硅胶植入物肉芽肿。

IF 4.4 3区医学

Eye Pub Date : 2026-10-02 DOI: 10.1038/s41433-026-04961-9

Kalu Jin, Jing Li, Jianmin Ma

引用次数: 0

Three-year real-world outcomes of faricimab in pretreated eyes with treatment-resistant neovascular age-related macular degeneration. faricimab在治疗抵抗性新生血管性老年性黄斑变性前治疗的三年真实结果

IF 4.4 3区医学

Eye Pub Date : 2026-10-02 DOI: 10.1038/s41433-026-04916-0

Pierluigi Daniele, Christine Goodchild, Eslam Ahmed, Anastasios Bisoukis, Serena Salvatore

引用次数: 0

Efficacy and safety of 0.01% atropine in Chinese children with nearwork-induced transient myopia: a randomised, double-blind, placebo-controlled trial. 0.01%阿托品治疗中国儿童近视的疗效和安全性：一项随机、双盲、安慰剂对照试验

IF 4.4 3区医学

Eye Pub Date : 2026-10-01 DOI: 10.1038/s41433-026-04534-w

Yunwei Fan, Yaguang Peng, Yan Zhang, Jiawen Wang, Yanan Guo, Xiaoxia Peng, Xueqing Bai, Man Hu, Yuan Wang, Jingjing Jiang, Wen Liu, Jifeng Yu, Manjun Liu, Qian Ding, Yue Yuan, Xiaomei Liu, Shaopeng Yang, Xiaoling Wang, Li Li

{"title":"Efficacy and safety of 0.01% atropine in Chinese children with nearwork-induced transient myopia: a randomised, double-blind, placebo-controlled trial.","authors":"Yunwei Fan, Yaguang Peng, Yan Zhang, Jiawen Wang, Yanan Guo, Xiaoxia Peng, Xueqing Bai, Man Hu, Yuan Wang, Jingjing Jiang, Wen Liu, Jifeng Yu, Manjun Liu, Qian Ding, Yue Yuan, Xiaomei Liu, Shaopeng Yang, Xiaoling Wang, Li Li","doi":"10.1038/s41433-026-04534-w","DOIUrl":"https://doi.org/10.1038/s41433-026-04534-w","url":null,"abstract":"Background: Nearwork-induced transient myopia (NITM) is a temporary reduction in distance vision following prolonged nearwork and is associated with an increased risk of myopia progression. This study aimed to evaluate the efficacy and safety of 0.01% atropine in controlling NITM in Chinese children.Methods: This randomised, double-blind, placebo-controlled trial enrolled Chinese children aged 6-15 years with myopia. Participants were randomised 1:1 to receive 0.01% atropine or placebo eye drops once nightly for 12 weeks, followed by a 12-week observation period. The primary endpoint was the change in initial NITM values from baseline to week 12.Results: A total of 148 participants were randomised to the 0.01% atropine group (n = 74) or placebo group (n = 74). The mean change in initial NITM from baseline to week 12 was 0.61 ± 0.31 dioptres (D) in the 0.01% atropine group versus 0.18 ± 0.56 D in the placebo group (P < 0.001). Significant differences were also observed in initial NITM at week 2 (-0.28 ± 0.16 D vs. -0.47 ± 0.42 D, P = 0.001) and week 12 (-0.08 ± 0.09 D vs. -0.52 ± 0.30 D, P < 0.001). The repeated measures analysis of variance demonstrated significantly improvements in initial NITM values in the 0.01% atropine group at week 2 (P = 0.047) and week 12 (P < 0.001) compared to placebo. Adverse events (AEs) were reported in 27 participants (37.0%) in the 0.01% atropine group and 30 participants (41.7%) in the placebo group. No serious AEs were reported.Conclusion: Atropine (0.01%) significantly reduces initial NITM values in myopic children, demonstrating sustained benefits up to 12 weeks post-treatment and a favourable safety profile.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retinal capillary haemangioblastoma with localised serous retinal detachment. 视网膜毛细血管母细胞瘤伴局限性浆液性视网膜脱离。

IF 4.4 3区医学

Eye Pub Date : 2026-10-01 DOI: 10.1038/s41433-026-04944-w

Mustafa Kamal Hallak, Robin Splawski, Robert Patrick Finger

引用次数: 0

Eye最新文献